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The vaccinia F11 protein promotes viral spread by
modulating the cortical actin cytoskeleton by inhibit-
ing RhoA signaling via an unknown mechanism. PDZ
domains are widely conserved protein interaction
modules whose occurrence in viral proteins is un-
precedented. We found that F11 contains a central
PDZ-like domain that is required to downregulate
RhoA signaling and enhance viral spread. The PDZ-
like domain interacts with the PDZ binding motif of
the Rho GTPase-activating protein (GAP) Myosin-
9A. In the absence of Myosin-9A, RhoA signaling is
not inhibited, resulting in fewer actin tails and
reduced virus release concomitant with less viral
spread. The loss of Myosin-9A GAP activity or its
ability to bind F11 also reduces actin tail formation.
Furthermore, the ability ofMyosin-9A topromote viral
spread dependson F11bindingRhoA. Thus, F11 acts
as a functional PDZ-containing scaffolding protein to
inhibit RhoA signaling by binding Myosin-9A.
INTRODUCTION
Given that RhoGTPases play an essential role in regulating a
wide variety of cellular processes, it is not surprising that their
signaling is modulated by many different viruses, especially dur-
ing actin-dependent entry (Chandran, 2010; Favoreel et al.,
2007; Mercer and Helenius, 2012; Mercer et al., 2010b; Quetglas
et al., 2012; Sa´nchez et al., 2012; Stolp and Fackler, 2011;
Taylor et al., 2011; Van den Broeke and Favoreel, 2011; Van
den Broeke et al., 2009). In the case of Vaccinia virus, entry tran-
siently activates Cdc42, Rac, and RhoA signaling (Locker et al.,
2000; Mercer and Helenius, 2008; Mercer et al., 2010a). During
the later stages of infection, however, Vaccinia downregulates
the steady-state level of GTP-bound Cdc42, Rac, and RhoA
(Arakawa et al., 2007b). The mechanism by which Vaccinia re-
duces Cdc42 and Rac signaling during infection remains to be
determined. In contrast, we have previously demonstrated that
Vaccinia inhibits RhoA signaling using F11, a viral protein thatCis expressed from as early as 2 hr postinfection (Arakawa
et al., 2007b; Cordeiro et al., 2009; Valderrama et al., 2006).
F11 interacts directly with RhoA using a motif that is also found
in the RhoA effector ROCK (Cordeiro et al., 2009; Valderrama
et al., 2006). F11-mediated inhibition of RhoA signaling is
responsible for stimulating Vaccinia-induced cell migration (Mo-
rales et al., 2008; Valderrama et al., 2006). Moreover, the intro-
duction of the Vaccinia F11L gene into the genomes of Modified
Vaccinia Ankara (MVA) and Myxoma viruses, which do not
possess an F11 ortholog promotes virus-induced cell migration
(Irwin and Evans, 2012; Zwilling et al., 2010).
F11-dependent inhibition of RhoA signaling also stimulates
increased microtubule dynamics and targeting to the plasma
membrane (Arakawa et al., 2007b). These changes aid newly
assembled viruses, undergoing kinesin-1-dependent microtu-
bule transport, to reach the plasmamembrane from their perinu-
clear site of assembly (Dodding et al., 2011; Geada et al., 2001;
Hollinshead et al., 2001; Rietdorf et al., 2001; Ward and Moss,
2001a, 2001b). Inhibition of RhoA signaling to mDia, a key regu-
lator of actin polymerization, also enhances Vaccinia release
from infectedHeLa cells bymodulating the cortical actin beneath
the plasma membrane (Arakawa et al., 2007a; Cordeiro et al.,
2009). The cortical actin, which is regulated by RhoA signaling
and provides the cell with mechanical resilience (Bergert et al.,
2012; de Curtis and Meldolesi, 2012; Fritzsche et al., 2013; Sal-
breux et al., 2012), represents a physical barrier that has to be
actively remodeled during exocytosis (Gutie´rrez, 2012; Nightin-
gale et al., 2012; Wollman and Meyer, 2012). It is also a signifi-
cant obstacle to the spread of viral infection, as it has to be
traversed or manipulated by newly assembled virus particles
before they can fuse with the plasma membrane (Radtke et al.,
2006; Taylor et al., 2011; Ward, 2011). Consistent with this, the
loss of F11 expression and the absence of RhoA inhibition impair
Vaccinia spread both in cell monolayers and in vivo, in an intra-
nasal mouse model of infection (Cordeiro et al., 2009).
Conversely, a recombinant Myxoma virus expressing F11 is
significantly more effective in cell-to-cell spread, as plaques
expand 6-fold faster and are four times larger than the control
(Irwin and Evans, 2012). The presence of F11 homologs in diver-
gent chordopoxviruses (http://www.poxvirus.org/) suggests that
F11-mediated inhibition of RhoA signaling plays a conserved role
in promoting viral spread.ell Host & Microbe 14, 51–62, July 17, 2013 ª2013 Elsevier Inc. 51
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F11 Binds Myosin-9A Using a PDZ DomainF11 interacts directly with RhoA (Arakawa et al., 2007b; Cor-
deiro et al., 2009; Valderrama et al., 2006). Nevertheless, we still
do not know the mechanistic basis of F11-mediated inhibition of
RhoA signaling during vaccinia infection. In the current study, we
have demonstrated that F11 interacts with Myosin-9A using a
central PDZ-like domain. This interaction and the GAP activity
of Myosin-9A are required to downregulate RhoA and enhance
the spread of infection. Our data demonstrate that F11 repre-
sents an unprecedented example of a viral protein with a func-
tional PDZ domain that acts as a scaffolding protein to inhibit
RhoA signaling.
RESULTS
F11Contains aCentral PDZ-like Domain andC-Terminal
PDZ-Binding Motif
Comparison of the amino acid sequence of Vaccinia F11 with or-
thologs in other chordopoxviruses shows that the central portion
is more conserved than the rest of the molecule (Figure 1A).
Structural predictions of residues 118–205 of Vaccinia F11 using
the Phyre server (http://www.sbg.bio.ic.ac.uk/phyre/) suggest
that this region would adopt a PDZ-like fold (Figure 1B). Consis-
tent with this, Vaccinia F11 and its orthopoxvirus homologs
contain a K/RxxxxxGF motif that is often a characteristic feature
of PDZ domains, as it is involved in direct interactions with PDZ
bindingmotifs (PBMs) (Figure 1B) (Luck et al., 2012; Nourry et al.,
2003). In addition, there is a highly conserved GD motif that is
found in nearly all PDZ domains, as it appears to be required
for the structural integrity of the PDZ fold (Figure 1B) (Kalyoncu
et al., 2010; Ponting, 1997). Interestingly, the amino acid
sequence of the vaccinia F11 C terminus also corresponds to
a class II PBM (Figure 1C).
PDZ-like Domain InteractionsRegulate theAbility of F11
to Bind RhoA
To investigate whether the central PDZ-like domain interacts
with the C-terminal PBM, we performed in vitro PBM peptide
pull-down assays on the F11-PDZ-like domain produced in
E. coli. We found that a peptide containing the C-terminal PBM
of F11 is capable of interacting with the F11 PDZ-like domain
(Figure 2A). Mutation of the conserved GF motif within PDZ do-
mains will weaken and/or abolish PBM interactions, while loss
of the GD motif is predicted to disrupt the PDZ fold. To investi-
gate whether mutation of the GF and GD motifs impacts on
F11-PBM binding, we generated recombinant Western Reserve
(WR) viruses expressing F11-GF/AA and F11-GD/AA (Figure 2B).
Using these viruses together with WR (wild-type F11), we per-
formed peptide pull-down assays on infected cell lysates
(Figure 2C). We found that alanine substitution of the GF motif
substantially reduces the interaction of full-length F11 with its
C-terminal PBM, while mutation of the GD motif largely abro-
gated all binding (Figure 2C).
Given these data, we wondered whether an intramolecular
interaction between the PDZ-like domain and the PBM regulates
the ability of F11 to interact with RhoA. To explore this possibility,
we performed in vitro pull-down assays using GTP-loaded GST-
RhoA on E. coli extracts containing full-length, untagged F11 and
a truncated version of the protein lacking its C-terminal PBM
(F11-DPBM) (Figure 2D). The truncated F11 showed markedly52 Cell Host & Microbe 14, 51–62, July 17, 2013 ª2013 Elsevier Inc.increased RhoA binding compared to the full-length wild-type
protein. However, this effect was abrogated by the introduction
of the GF/AA and GD/AA mutations into the PDZ-like domain
(Figure 2D). This latter result was unexpected, as the RhoA bind-
ing site in F11 is located toward the C terminus of the molecule
(residues 299–312), away from the central PDZ-like domain (res-
idues 118–205) (Figure 1A).
The RhoA binding site in F11 is strikingly similar to that of
ROCK, which is found within a coiled-coil dimer interface that in-
volves two molecules (Dvorsky et al., 2004). Given that F11 also
interacts with itself (Arakawa et al., 2007a), we wondered
whether the lack of RhoA binding by the F11 GF/AA and GD/
AA mutants is because the PDZ-like domain is required for
this self-association. Consistent with this notion, pull-down
assays from infected cell lysates reveal that F11-GF/AA and
F11-GD/AA have reduced self-association when compared to
wild-type full-length F11 (Figure 2E). Pull-down assays on ex-
tracts from cells coexpressing GFP and FLAG-tagged PDZ-
like domain or the C-terminal region of F11 reveal that they are
also capable of interacting with themselves (Figure 2F). Our
data suggest that an interaction between PDZ-like domains
and the C-terminal PBM regulates the ability of F11 to interact
with RhoA.
The F11 PDZ-like Domain Is Required to Inhibit RhoA
and Promote Viral Spread
Consistent with our in vitro pull-down assays using GST-RhoA,
we found that in contrast to WR, but similar to DF11L, the F11-
GF/AA or F11-GD/AA viruses did not reduce the level of GTP-
bound RhoA at 8 hr postinfection (Figure 3A). Our previous
observations have shown that F11-mediated inhibition of RhoA
signaling enhances the ability of intracellular enveloped virions
(IEVs) to traverse the cortical actin and fuse with the plasma
membrane, prior to inducing actin tails or being released from
the infected cell (Arakawa et al., 2007b; Cordeiro et al., 2009).
The average number of actin tails per cell can therefore be
used to assess the ability of F11 to downregulate RhoA signaling.
We found that the DF11L, F11-GF/AA, and F11-GD/AA viruses
induce significantly fewer actin tails than the WR virus from
which they are derived (Figure 3B). These mutant viruses also
had reduced cell-to-cell spread as they formed smaller plaques
than WR on confluent cell monolayers (Figure 3C). In addition,
the release of infectious virus particles into the media is equally
reduced for all three viruses compared toWR (Figure 3D). Collec-
tively, our observations demonstrate that the PDZ-like domain is
required for F11 to downregulate RhoA signaling and enhance
the spread of infection.
The PDZ Binding Motif Promotes the Association of F11
with Membranes
Our earlier observations demonstrate that an interaction be-
tween the PDZ-like domain and the C-terminal PBM regulates
the ability of F11 to bind RhoA (Figure 2D). Given this, we
wondered whether removal of the C-terminal PBM would render
F11 constitutively active for RhoA binding and enhance viral
spread. To investigate if this is the case, we generated a recom-
binant WR virus expressing F11-DPBM (Figure 4A). Unexpect-
edly, cells infected with the DF11L and F11-DPBM viruses
had significantly fewer actin tails than those infected with WR
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Figure 1. F11 Contains a Conserved Central PDZ-like Domain
(A) Shows the sequence homology between N-terminal, central, and C-terminal regions of vaccinia Western Reserve (WR) F11 and other poxvirus orthologs. The
red asterisk on F11 indicates the position of the RhoA binding site. The table shows the sequence conservation between the full-length F11 orthologs.
(B) Sequence alignment of the predicted F11 PDZ-like domains from the indicated poxviruses. The position of the predicted b sheet (green) and a helix (purple)
secondary structure elements as well as the conserved GD and K/RxxxxxGF motifs are indicated.
(C) Sequence alignment of the three different classes of C-terminal PDZ binding motifs (PBM) together with the last four amino acid residues of vaccinia F11. X
represents any amino acid and f indicates a hydrophobic residue.
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F11 Binds Myosin-9A Using a PDZ Domain(Figure 4B). They also released less infectious virus into the me-
dia than WR (Figure 4C). PBMs play an important role in target-
ing proteins to specific cellular compartments (Ivarsson, 2012;
Luck et al., 2012; Nourry et al., 2003; Subbaiah et al., 2011).CWe therefore investigated whether loss of its PBM impacts on
the cytosolic and membrane distribution of F11. We found
that F11-DPBM had reduced membrane association as
compared to F11 (Figure 4D). We assume that the decrease inell Host & Microbe 14, 51–62, July 17, 2013 ª2013 Elsevier Inc. 53
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Figure 2. The PDZ-like Domain Mediates
F11 Dimerization and PBM Interactions
(A) Immunoblot analysis of in vitro peptide pull-
downs showing that the predicted F11 PDZ-like
domain (tagged with MBP) produced in E. coli in-
teracts with a peptide containing the C-terminal
PBM of F11.
(B) Immunoblot analysis of lysates from HeLa cells
infected with the indicated viruses for 3 hr. The
WR, F11-GF/AA, and F11-GD/AA viruses express
equivalent amounts of F11. A36 and actin repre-
sent viral and host loading controls respectively.
Non, uninfected control.
(C) Immunoblot analysis of in vitro peptide pull-
down assays on infected cell extracts reveals
that mutation of the conserved GF and GD
motifs in full-length F11 weakens or abolishes
their respective interactions with a F11 PBM
peptide.
(D) Immunoblot analysis of pull-downs reveals
that F11 is unable to interact with purified
GTPgS-bound GST-RhoA in vitro in the presence
of its PBM or when the GF and GD motifs are
mutated.
(E) Immunoblot analysis of pull-downs on DF11L-
infected cells coexpressing only GFP and FLAG-
tagged wild-type (WT), GF/AA, or GD/AA F11.
Mutation of the GF and GD motifs disrupts the
ability of F11 to self-associate.
(F) Pull-downs on DF11L-infected cells coex-
pressing GFP- and FLAG-tagged PDZ (F11-PDZ)
or C-terminal (F11-CT) regions of F11. The blot
reveals that the PDZ and C-terminal regions of F11
can self-associate. GFP alone represents the
negative control.
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F11 Binds Myosin-9A Using a PDZ Domainthe number of actin tails and release of infectious virus is
because the reduced membrane association of F11-DPBM im-
pairs its ability to downregulate RhoA signaling at the plasma
membrane.
The F11 PDZ-like Domain Interacts with the RhoGAP
Myosin-9A
It is possible that the function of the PDZ-like domain is to pro-
mote dimerization of F11 to allow it to sequester RhoA to inhibit
its downstream signaling. However, WR infection leads to an
F11-dependent reduction in the steady-state levels of GTP-
bound RhoA (Arakawa et al., 2007b; Cordeiro et al., 2009; Val-
derrama et al., 2006). This suggests that the F11 PDZ-like
domain has a more direct role in downregulating RhoA
signaling, presumably by interacting with an unknown binding
partner.
In recent years, it has become clear that the cellular targeting
of multiple RhoGTPase-activating Rho-GEFs is dependent on
their interaction with PDZ-containing scaffolding proteins (Gar-
cı´a-Mata and Burridge, 2007). It is also striking that PBMs are
also enriched in Rho-GAPs, which promote inactivation of
RhoGTPases, when compared to other protein families (Giallour-54 Cell Host & Microbe 14, 51–62, July 17, 2013 ª2013 Elsevier Inc.akis et al., 2006). Eighteen of the 80 Rho-
GAPs in the human genome have a
predicted PBM at their C terminus (see
Figure S1A online). Given our earlier ob-servations, we hypothesized that the F11 PDZ-like domainmedi-
ates downregulation of RhoA signaling by interacting with a class
II PBM containing Rho-GAP. To explore this possibility, we per-
formed in vitro PBM peptide pull-down assays with the seven
Rho-GAPs that have a class II PBM (Figure 5A). We found that
only b-Chimaerin (CHN2) and Myosin-9A interacted with the
PDZ-like domain of F11. We focused our attention on Myosin-
9A, as it has been reported to regulate RhoA activity and cortical
actin during cell-cell adhesion (Chieregatti et al., 1998; Omel-
chenko and Hall, 2012), while b-Chimaerin is a Rac-specific
GAP (Yang and Kazanietz, 2007).
In vitro pull-down assays reveal that the deletion of the PBM in
a peptide corresponding to the C terminus of Myosin-9A abol-
ishes its interaction with the isolated F11 PDZ-like domain pro-
duced in E. coli (Figure 5B). The native Myosin-9A PBM peptide
was also unable to interact with full-length F11-GF/AA and F11-
GD/AA from infected cell lysates (Figure 5B). This interaction is
not unique to the Myosin-9A PBM peptide, as endogenous
Myosin-9A coimmunoprecipitates with F11 from infected cell ly-
sates (Figure 5C, Figure S1B). Moreover, GFP-Trap pull-downs
reveal that deletion of the C-terminal PBM of Myosin-9A abol-
ishes its interaction with endogenous F11 (Figure 5C).
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Figure 3. The PDZ-like Domain Is Required
to Inhibit RhoA and Promote Viral Spread
(A) Quantitative immunoblot analysis reveals that
WR but not DF11L, F11-GF/AA, or F11-GD/AA
viruses reduces the level of GTP-bound RhoA at
8 hr postinfection relative to noninfected controls.
Error bars represent standard error of the mean
(SEM) from seven independent experiments; *p <
0.05.
(B) Immunofluorescence images of actin tails
formed by the indicated viruses at 8 hr post-
infection. B5 is an IEV (intracellular enveloped
virion) protein that accumulates in the trans-Golgi
network and also labels virus particles inducing
actin tails. The graph shows that WR induces
significantly more actin tails than the DF11L, F11-
GF/AA, or F11-GD/AA viruses. At least 50 cells
were counted in four independent experiments for
each virus with error bars representing the SEM
and ***p < 0.001.
(C) Representative images of plaques formed in
BSC-1 confluent monolayers by the indicated vi-
ruses 4 days postinfection. The graph shows that
WR induces significantly larger plaques than the
other viruses. The number of plaques analyzed
over three independent experiment is indicated,
with error bars representing the SEM and **p <
0.01.
(D) The graph shows that cells infected with WR
release 2-fold more infectious virus into the me-
dia than those infected with DF11L, F11-GF/AA, or
F11-GD/AA viruses. Error bars represent the SEM
from five independent experiments; *p < 0.05.
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F11 Binds Myosin-9A Using a PDZ DomainMyosin-9A Enhances Actin Tail Formation and Virus
Release
To determine the functional significance of the interaction be-
tween F11 and Myosin-9A, we examined the consequence of
RNAi-mediated depletion of Myosin-9A on F11-dependent inhi-
bition of RhoA signaling (Figures 6A and 6B). Loss of Myosin-9A
results in a significantly higher level of GTP-bound RhoA in WR-
infected HeLa cells at 8 hr postinfection compared to control
RNAi-treated cells (Figure 6B). In contrast, there is no significant
difference in the level of GTP-bound RhoA in Myosin-9A and
control RNAi-treated cells following infection with the DF11L vi-
rus (Figure 6B). Consistent with this, Myosin-9A RNAi-treated
HeLa cells infected with WR but not DF11L have significantly
fewer actin tails (Figure 6C). We also found that the release of in-
fectious virus into the media was also reduced for WR, but not
DF11L (Figure 6D). In addition, in contrast to the wild-type pro-
tein, we found that GFP-tagged Myosin-9A-DPBM that cannot
bind F11 (Figure 5C) is unable to enhance actin tail formation
in WR-infected HeLa cells treated with siRNA against the
30UTR of human Myosin-9A (Figures 6E and 6F). A Myosin-9ACell Host & Microbe 14, 5mutant lacking its GAP activity is equally
deficient in actin tail formation (Figures
6E and 6F). These data demonstrate
that the interaction of Myosin-9A with
the F11-PDZ-like domain together with
its GAP activity are required for F11 to
enhance the ability of the virus to fusewith the plasma membrane to facilitate actin tail formation and
release.
F11 Acts as a PDZ Scaffolding Protein to Enhance Viral
Spread
To directly assess the impact of the loss of Myosin-9A on the
cell-to-cell spread of the virus, we used human A549 cells, which
form confluent monolayers suitable for plaque analysis (Humph-
ries et al., 2012). As seen in HeLa cells, RNAi-mediated loss of
Myosin-9A resulted in reduction in actin tail formation in WR
but not DF11L-infected A549 cells (Figures 7A and 7B). We
also found that WR formed significantly smaller plaques in the
absence of Myosin 9A (Figure 7C). In contrast, the plaques
formed by the DF11L virus were the same size regardless of
the presence or absence of Myosin-9A (Figure 7C). We also
found that the loss of Myosin 9A did not impact on the size of pla-
ques formed by the F11-VK virus, which expresses an F11
mutant that is deficient in RhoA binding (Cordeiro et al., 2009).
The similar phenotype of the DF11L and F11-VK viruses sug-
gests that Myosin-9A only acts on RhoA when it is bound to1–62, July 17, 2013 ª2013 Elsevier Inc. 55
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Figure 4. The F11 PBM Promotes Its Associa-
tion with Membranes
(A) Immunoblot analysis of lysates from HeLa cells
infected with the indicated viruses for 3 hr. A36 and
actin represent viral and host loading controls,
respectively. Non, uninfected control.
(B) Immunofluorescence images of actin tails formed
by the indicated viruses at 8 hr postinfection. B5 is an
IEV (intracellular enveloped virion) protein that ac-
cumulates in the trans-Golgi network and also labels
virus particles inducing actin tails. The graph shows
that DF11L and F11-DPBM-infected cells have
significantly less actin tails than those infected with
WR. At least 50 cells were counted in four indepen-
dent experiments for each virus, with error bars
representing the SEM and ***p < 0.001.
(C) The graph shows that cells infected with the
DF11L and F11-DPBM viruses release less infectious
virus into the media than those infected with WR.
Error bars represent the SEM from three independent
experiments, and ***p < 0.001.
(D) Cell homogenates from Hek293T cells expressing
GFP or GFP-tagged F11 or F11-DPBM were
separated into cytosolic (C) and membrane (M)
fractions and subjected to immunoblotting. Hsp90
and Transferrin receptor (Tfr) represent endogenous
markers for the cytosolic and membrane fractions,
respectively. The graph shows the percentage of
protein in the membrane fraction (membrane/
cytosol + membrane) determined from three inde-
pendent experiments by quantitative immunoblot
analysis. Error bars represent the SEM; *p < 0.05.
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F11 Binds Myosin-9A Using a PDZ DomainF11. Consistent with this notion, coimmunoprecipitation experi-
ments demonstrate that FLAG-F11 forms complexes with
endogenous Myosin-9A and RhoA during WR infection (Fig-
ure 7D). The detection of this trimolecular complex suggests
that F11 is acting as a PDZ scaffolding protein to bring
Myosin-9A in close association with GTP-bound RhoA during
infection.
DISCUSSION
F11 Contains a Functional PDZ-like Domain
Our previous observations have demonstrated that F11 pro-
motes the spread of Vaccinia virus by inhibiting RhoA signaling
at the later stages of infection (Arakawa et al., 2007b; Cordeiro
et al., 2009; Valderrama et al., 2006). F11-mediated inhibition of
RhoA has many effects on infected cells, including increasing
microtubule dynamics and stimulating cell migration (Arakawa
et al., 2007b; Cordeiro et al., 2009; Irwin and Evans, 2012; Mo-
rales et al., 2008; Valderrama et al., 2006; Zwilling et al., 2010).
However, it is the loss of the ability of RhoA to regulate the56 Cell Host & Microbe 14, 51–62, July 17, 2013 ª2013 Elsevier Inc.cortical actin beneath the plasma mem-
brane that enhances viral spread, as it
facilitates increased actin tail formation
and virus release from infected cells
(Arakawa et al., 2007a; Cordeiro et al.,
2009). The ability of F11 to mediate RhoA
inhibition is dependent on its direct inter-
action with RhoA using a motif close tothe C terminus of the molecule (Cordeiro et al., 2009; Valder-
rama et al., 2006). We have now demonstrated that a central
PDZ-like domain is also required for F11 to inhibit RhoA
signaling and enhance the spread of infection.
PDZ domains are protein interaction domains that were first
identified almost 20 years ago in three unrelated proteins:
Postsynaptic Density Protein (PSD-95), Discs-Large (Dlg), and
Zonula Occludens-1 (ZO-1) (Ivarsson, 2012; Subbaiah et al.,
2011). PDZ domains are typically 80–90 residues in length
with 30% sequence identity and adopt a globular fold
consisting of six b strands and two a helices (Ivarsson, 2012;
Subbaiah et al., 2011). They are conserved from bacteria to
man, with the human genome encoding about 270 different
PDZ domains (Luck et al., 2012; Nourry et al., 2003; Ponting,
1997). PDZ domains most frequently interact with short peptide
motifs found at the extreme C termini of proteins. There are
three different classes of C-terminal PBMs, all of which end
with a hydrophobic residue. PDZ domains also bind internal
peptide motifs, hetero- and/or homodimerize, and interact
with lipids (Ivarsson, 2012; Luck et al., 2012; Nourry et al.,
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Figure 5. F11 Interacts with the PBM of
Myosin-9A
(A) Immunoblot analysis of in vitro peptide
pull-downs reveals that the F11 PDZ-like
domain binds to the class II PBM of b-Chimaerin
(CHN2) and Myosin-9A (MYO9A). The table in-
dicates the last eight amino acids of each
RhoGAP and their known specificity toward
RhoGTPases.
(B) (Left) Immunoblot analysis of in vitro pull-
downs reveals that the F11 PDZ-like domain
cannot bind a Myosin-9A PBM peptide lacking the
last four amino acids (DPBM). (Right) Disruption of
the GF and GD motifs weakens and disrupts the
interaction of full-length F11 with the Myosin-9A
PBM peptide, respectively.
(C) (Left) Immunoblot analysis reveals that
FLAG-tagged F11 expressed by its natural pro-
moter in the viral genome coimmunoprecipitates
with endogenous Myosin-9A. Non, uninfected
control. (Right) F11 interacts with GFP-tagged
myosin-9A (WT) but not a mutant lacking its
C-terminal PBMmotif (DPBM). (Figure 5, related to
Figure S1).
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F11 Binds Myosin-9A Using a PDZ Domain2003; Subbaiah et al., 2011). The diversity of their interactions
and abundance allows PDZ-containing proteins to participate
in a multitude of cellular functions including adhesion, polarity,
proliferation, apoptosis, and signaling. Given the importance of
PDZ interactions in so many fundamental cellular processes, it
is not surprising that their function is frequently targeted during
infection by viral proteins containing PBMs (Davey et al., 2011;
Javier and Rice, 2011). What is perhaps more surprising is
the lack of evidence for viruses manipulating their hosts using
virally encoded PDZ domain-containing proteins (Ivarsson,
2012; Subbaiah et al., 2011).
F11 represents an unprecedcented example of a viral
protein containing a functional PDZ-like domain. Furthermore,
the F11 PDZ-like domain is widely conserved, even in very
divergent Chordopoxvirinae such as Lumpy skin disease
virus (LSDV026 47%), Molluscum contagiosum virus
(MC018L 38%), ORF virus (ORF009 38%), Bovine papular sto-
matitis virus (ORF009 38%), Canarypox (CNPV137 32%), and
Fowlpox (FVP110 29%). F11 is, however, noticeably absent
from Leporipox, Suipox, and Yatapox viruses as well as
some Capripox viruses (Goat and Sheep) (http://poxvirus.org/
). Interestingly, in contrast to F11 encoding Orthopoxviruses,
Myxoma (Leporipox) and Yaba-like disease (Yatapox) viruses
do not form clearing plaques on confluent cell monolayers
(M.P.D. and M.W., unpublished data) (Irwin and Evans,
2012). Deletion of the F11L gene from Vaccinia (WR) also leadsCell Host & Microbe 14, 5to a loss of central plaque clearing,
while expression of F11 during Myxoma
infection promotes the formation of
clearing plaques (Cordeiro et al., 2009;
Irwin and Evans, 2012). Central plaque
clearing, which involves loss of cell-cell
contact and virus-induced cell migration
(Cordeiro et al., 2009), may therefore beindicative of F11-mediated inhibition of RhoA signaling during
poxvirus infection.
Molecular Interactions in F11 Regulate RhoA Binding
We previously found that GST-tagged F11 interacts directly with
GTP-bound RhoA using a motif that is related to the RhoA
binding site in ROCK (Cordeiro et al., 2009; Dvorsky et al.,
2004; Valderrama et al., 2006). Unexpectedly, we have now
found that recombinant untagged F11 is incapable of interacting
with GTP-bound RhoA. Removal of the C-terminal F11 PBM,
however, allows the interaction with RhoA to occur. This sug-
gests that the ability of F11 to bind RhoA is regulated by an intra-
molecular interaction between its PDZ-like domain and the
C-terminal PBM. To further test this notion, we examined
whether RhoA can bind F11-GF/AA and F11-GD/AA, which are
deficient in PBM interactions. Contrary to our expectations,
these F11 mutants were also unable to bind GTP-bound RhoA.
Structural analysis has demonstrated that RhoA binding to
ROCK involves engagement with two molecules forming a
parallel a-helical coiled-coil dimer (Dvorsky et al., 2004). We
have also previously demonstrated that F11 is capable of
undergoing intermolecular interactions (Arakawa et al., 2007a).
We now found that the PDZ-like domain is required for the
self-association of F11, which presumably reflects oligomeriza-
tion of the molecule. Our pull-down assays clearly demonstrate
that, as observed with other PDZ domains (Chen et al., 2008),1–62, July 17, 2013 ª2013 Elsevier Inc. 57
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Figure 6. Myosin-9A-Dependent Downregulation of RhoA Promotes Viral Release
(A) RT-qPCR and immunoblot analysis of Myosin-9A expression in HeLa cells treated with the indicated RNAi oligos. For RT-qPCR, the error bars represent SEM
from three independent experiments; **p < 0.01.
(B) Quantitative immunoblot analysis reveals that the level of GTP-bound RhoA is higher in WR- but not DF11L-infected cells in the absence of Myosin-9A. Error
bars represent SEM from three independent experiments. NS, not significant; *p < 0.05 and **p < 0.01.
(C) Representative immunofluorescence images of the actin cytoskeleton in WR-infected cells treated with control or Myosin-9A RNAi. Loss of Myosin-9A re-
duces the number of actin tails in WR- but not DF11L-infected cells. At least 50 cells were analyzed in three independent experiment for each condition; the error
bars show SEM; ***p < 0.001.
(D) The graph shows that loss of Myosin-9A results in 2-fold reduction in the percentage of infectious virus released into the media from WR- but not DF11L-
infected cells. The error bars represent SEM from five independent experiments; NS, not significant; **p < 0.01 and ***p < 0.001.
(E) Representative immunofluorescence images of the actin cytoskeleton in WR-infected cells treated with RNAi directed against the 30UTR of Myosin-9A and
expressing the indicated GFP-tagged Myosin-9A clone at 8 hr postinfection.
(F) Loss of Myosin-9A GAP activity or its PBM reduces the number of actin tails in WR-infected cells. At least 50 cells were counted in four independent
experiments for each condition with error bars indicating SEM and ***p < 0.001.
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Figure 7. Myosin-9A-Dependent Downre-
gulation of RhoA Promotes Viral Spread
(A) Immunoblot analysis of Myosin-9A expression
in A549 cells treated with RNAi directed against
the 30UTR of Myosin-9A.
(B) Quantitative analysis of actin tail formation in
Myosin-9A RNAi-treated A549 cells infected with
the indicated virus at 8 hr postinfection. At least 50
cells were counted in three independent experi-
ments for each virus, with error bars indicating
SEM and ***p < 0.001.
(C) Images of plaques formed by the indicated vi-
ruses on A549 cell monolayers 3 days post-
infection after treatment with control or Myosin-9A
RNAi. The graph shows the quantification of pla-
que sizes. Error bars represent SEM from three
independent experiments in which a total of 150
plaques were measured and ***p < 0.001.
(D) Immunoblot analysis reveals that virally ex-
pressed FLAG-tagged F11 coimmunoprecipitates
with endogenous Myosin-9A and RhoA.
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F11 Binds Myosin-9A Using a PDZ Domainthe isolated PDZ-like domain can ‘‘dimerize.’’ However, it is likely
that the C-terminal third of the molecule (residues 223–348) also
contributes to F11 oligomerization, as it is capable of binding to
itself in the absence of the rest of the molecule. This property is
consistent with its predicted a-helical nature and similarities to
the RhoA binding region of ROCK (Dvorsky et al., 2004).
The oligomerization of F11 immediately raises the issue of
whether the PBM-PDZ-like domain interactions occur in cis or
in trans. Structural analysis is clearly required to provide a
detailed molecular understanding of F11 and how PBM-PDZ-
like domain interactions regulate RhoA binding. It also remains
to be established what disrupts the interaction of the F11 PDZ-
like domain with its PBM during infection. One attractive possi-
bility is that the interaction with the Myosin-9A PBM ‘‘opens’’
F11 and facilitates RhoA binding. In addition, our data clearly
show that the C-terminal PBM of F11 enhances its association
with membranes, suggesting that F11 may interact with an addi-
tional PDZ domain-containing protein once it is ‘‘open.’’ It is alsoCell Host & Microbe 14, 5possible that the ability of F11 to interact
with RhoA is influenced by its interaction
with lipids in the plasma membrane, as
the loss of its PBM does not completely
abrogate membrane binding.
Myosin-9A Enhances Actin Tail
Formation and Virus Release
F11 does not only bind RhoA, it is also
responsible for reducing the level of
active GTP-bound RhoA during Vaccinia
infection (Arakawa et al., 2007b; Cordeiro
et al., 2009; Valderrama et al., 2006). Rho
GTPases are inactivated by GTPase-acti-
vating proteins (GAPs), which stimulate
the hydrolysis of GTP to GDP (Garcı´a-
Mata and Burridge, 2007). Interestingly,
as seen with Rho GTPase activating
Rho-GEFs, PBMs are enriched in Rho-
GAPs, when compared to other proteinfamilies (Garcı´a-Mata and Burridge, 2007; Giallourakis et al.,
2006). Eighteen of the 80 Rho-GAPS encoded in the human
genome have a C-terminal PBM, but only seven are class II.
Our Rho-GAP PBMpeptide pull-downs revealed that only b-Chi-
maerin (CHN2) andMyosin-9A interact with the PDZ-like domain
of F11.
Our previous observations suggest that release of vaccinia
is dependent on RhoA but not Rac or Cdc42 (Arakawa et al.,
2007a). Nevertheless, it is curious that the F11 PDZ-like domain
interacts with b-Chimaerin, a Rac-specific GAP (Yang and Kaza-
nietz, 2007). F11 does not bind Rac (Cordeiro et al., 2009; Valder-
rama et al., 2006). However, WR but not MVA, which lacks
a functional F11, downregulates Rac signaling at 8 hr post-
infection (Arakawa et al., 2007b). The interaction of Myosin-9A
with F11 is easier to rationalize as it regulates RhoA activity
and cortical actin during cell-cell adhesion (Chieregatti et al.,
1998; Omelchenko and Hall, 2012). RNAi-mediated loss of
Myosin-9A expression during WR infection resulted in a similar1–62, July 17, 2013 ª2013 Elsevier Inc. 59
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as observed in DF11L-infected cells. In contrast, an absence of
Myosin-9A had no impact on RhoA signaling and actin tail forma-
tion in DF11L-infected cells. This demonstrates that Myosin-9A
is clearly working in an F11-dependent fashion, as predicted
by our in vitro interaction data. This is also consistent with the
observation that GFP-Myosin-9A lacking its PBM does not pro-
mote increased actin tail formation in WR-infected HeLa cells
treated with siRNA against the 30UTR of human Myosin-9A.
The F11 Acts as PDZ Scaffolding Protein to Promote
Viral Spread
The ability of Myosin-9A to promote actin tail formation (inhibit
RhoA signaling) during WR infection clearly depends on its
GAP activity as well as its ability to bind the PDZ-like domain
of F11. However, the observation that the DF11L and F11-VK vi-
ruses form similar sized plaques regardless of the presence of
Myosin-9A suggests that the Rho-GAP only acts on RhoA
when it is bound to F11. It would also explain why treatment of
WR-infected cells with the RhoA inhibitor TAT-C3 reverses the
dominant-negative effects of expressing F11-VK on actin tail for-
mation and virus release (Arakawa et al., 2007a). In addition, this
hypothesis is also supported by the observation that the level of
GTP-bound RhoA is the same in HeLa cells infected with the
DF11L and F11-VK viruses at 8 hr postinfection (Cordeiro
et al., 2009). The most straightforward explanation for these
data is that F11 acts as a scaffold to bring Myosin-9A and
RhoA together. Consistent with this, we were able to detect
F11:Myosin-9A:RhoA complexes in infected cells. In summary,
our data indicate that F11 downregulates RhoA signaling by
mimicking the classic function of many cellular PDZ-containing
proteins by acting as a scaffolding protein to bring Myosin-9A
together with RhoA.
EXPERIMENTAL PROCEDURES
Antibodies and Infections
Antibodies against vaccinia A36 and B5 have been described (Hiller and
Weber, 1985; Ro¨ttger et al., 1999). The following antibodies were also used:
GFP 3E1 (Cancer Research UK), MBP 8G1 and RhoA 67B9 (Cell Signaling
Technology), and FLAG F7425 and b-actin AC-74 (Sigma-Aldrich). TheMyosin
9A antibody was a gift from Dr. Martin Ba¨hler (Institute of Molecular Cell
Biology, Westfalian Wilhelms University Mu¨nster, Germany) (Chieregatti
et al., 1998). The F11 antibody was produced by immunizing rabbits with a
peptide corresponding to residues 101–120 of F11 (PDIKLDAVLDRDGNFR-
PADC) coupled via the free C-terminal cysteine residue to KLH using the imject
activated immunoconjugation kit (Pierce Chemical Co.). F11 antibodies were
affinity purified on the same peptide coupled to a SulfoLink column (Pierce
Chemical Co.). Actin was stained with Alexa 488 or Texas red phalloidin (Invi-
trogen). HeLa, A549, and BS-C-1 cells were infected with WR or recombinant
vaccinia viruses and processed for immunofluorescence and immunoblot
analysis or actin tail quantification as described previously (Arakawa et al.,
2007a, 2007b).
Expression of F11-PDZ-like Domain and F11 PBM Pull-Down Assays
The open reading frame of the Maltose binding protein (MBP) was amplified
from pMAL-P2 (New England BioLabs, MA, USA) at the same time as inserting
a downstream 3C cleavage site by PCR and cloned into the Nde1-EcoRI of the
T7 bacterial expression vector pMW-GST (Garvalov et al., 2003). The DNA cor-
responding to the F11 PDZ-like domain (residues 118–205) was amplified by
PCR and cloned into the NotI-EcoRI site of pMW172-MBP to generate the
MBP-3C-F11-PDZ expression vector. MBP-3C-F11-PDZ was expressed in60 Cell Host & Microbe 14, 51–62, July 17, 2013 ª2013 Elsevier Inc.BL21(DE3) Rosetta cells by the addition of 1 mM IPTG for 4 hr at 30C and sol-
uble fractions prepared as previously described (Boe¨da et al., 2007). F11 PBM
(KNRDKIVNSLSLSNLDFRL) and DPBM (KNRDKIVNSLSLSNL) peptides were
coupled via an additional N-terminal cysteine to SulfoLink resin (Pierce Chem-
ical Co.) and used for pull-down assays on infected cell extracts or with MBP-
F11-PDZ produced in E. coli.
Recombinant F11 Viruses
The F11-GF/AA and F11-GD/AA viruses were generated using the same
strategy as that used to isolate the F11-VK mutant (Cordeiro et al., 2009).
The codons corresponding to Gly130 and Phe131 or Gly173 and Asp174
of the F11 gene in the DF11L targeting vector were mutated to encode
alanine. The targeting vectors were transfected into cells infected with the
DF11L virus. Fluorescence (mCherry) was used as a selectable marker to
isolate recombinant viruses by successive rounds of plaque purification. The
virus encoding FLAG-F11 was isolated using the same strategy as that to
isolate the GFP-F12 virus, except DF12L-infected cells were transfected
with a targeting vector encoding F12-FLAG-F11 rather than GFP-F12
(Dodding et al., 2009). The recombinant FLAG-F11 virus was isolated by
selecting for a recovery in plaque size similar to that of Vaccinia WR as well
as expression of FLAG-F11.
Rho Activation Assays
Rhotekin pull-down assays to assess the level of GTP-bound RhoA were per-
formed on lysates from HeLa cells infected for 8 hr as described previously
(Arakawa et al., 2007b). The ratio of activated to total RhoA was determined
in at least three independent experiments by quantitative immunoblot analysis
on an Odyssey Infrared Imaging System (LI-CORCorporate) as described pre-
viously (Cordeiro et al., 2009). The data are normalized as the percentage of
GTP-bound Rho in noninfected control cells.
Virus Release Assays
HeLa cells were infected with viruses at moi 3. Eight hours postinfection, in-
fected cells were washed twice, and tissue culture medium was added. Two
hours later, the tissue culture medium and cells were collected. The amount
of released infectious virus and intracellular viruses were subsequently as-
sessed by the plaque assay.
Plaque Assays
Confluent BS-C-1 cells were infected with WR, DF11, F11-GF/AA, and F11-
GD/AA viruses for 4 days; stained with crystal violet; and plaque areas quan-
tified as described previously (Arakawa et al., 2007a; Cordeiro et al., 2009). In
addition, human A549 cells transfected with Myosin 9A or control siRNA for
48 hr were infected with WR, DF11, or F11-VK viruses. Three days later, the
resulting plaques were stained with anti-B5 and quantified as described previ-
ously (Cordeiro et al., 2009; Humphries et al., 2012).
RhoGAP PBM Pull-Down Assays
The following PBMpeptides—ARHGAP6 (AWCGALRTFSSSLPYLMFL), CHN1
(IRYQRLVVELLIKNEDILF), CHN2 (MRYQKLIVQILIENEDVLF), ARHGAP11A
(PKHPIGKTQLLPTSKPVDL), MYO9A (PDCTSNQQLALFGNNEFMV), SRGAP3
(EGERAECGTTRIQDKLYRL), SYDE1 (DALILDLERELSKQINVCL), and F11
(KNRDKIVNSLSLSNLDFRL)—were coupled via an additional N-terminal biotin
to M-280 Streptavidin Dynabeads (Invitrogen). Coupled PBM peptides were
used for pull-down assays on purified recombinant MBP-F11-PDZ. A similar
strategy was followed for MYO9A-DPBM pull-downs using the peptide
(PDCTSNQQLALFGNN).
Myosin-9A Expression Vectors and Cell Lines
Human Myosin 9A and its R2098M GAP mutant were kindly provided by Prof.
Alan Hall (Cell Biology Program, Memorial Sloan-Kettering Cancer Center,
New York, USA) (Omelchenko and Hall, 2012). Myosin 9A, R2098M, and
DPBM (which lacks the last nine amino acid residues) were amplified by
PCR and cloned into the NotI-BamHI sites of the vaccinia and CMV expression
vectors pEL-N-GFP (Frischknecht et al., 1999) and pCB6-N-GFP (Rietdorf
et al., 2001), respectively.
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Purified GST-RhoA from E. coli was treated with 10 mM GTPgS for 30 min at
30C after addition of 10mMEDTA. GTPgS-loaded GST-RhoA resin was incu-
bated with E. coli soluble fraction containing F11, F11DPBM, F11DPBM-GF/
AA, or F11DPBM-GD/AA for 1 hr at 4C. The beads were washed three times
with bacterial lysis buffer (50 mM Tris-HCl [pH 8.0], 500 mM NaCl, 25% su-
crose, 10 mM MgCl2, 0.1% Triton-X, and protease inhibitors). Total input
and bound samples were subjected to SDS-PAGE and immunoblot analysis.
Separation of Membrane and Cytosolic Fractions
Hek293T cells were transfected with CMV expression vectors encoding GFP-
tagged F11 or F11-DPBM for 24 hr prior to the membrane and cytosolic frac-
tions being separated as described previously (Handa et al., 2007). Hek293T
cells expressing GFP-tagged F11 or F11-DPBM were suspended in 50 mM
Tris-HCl (pH 7.5), 0.2% Saponin with protease inhibitors and centrifuged at
17,400 g for 30 min at 4C. The supernatant was subsequently removed and
used as the cytosolic fraction. The pellet was resuspended in 50 mM Tris-
HCl (pH 7.5), 1% Triton-X with protease inhibitors and allowed to stand on
ice for 15 min before being centrifuged at 17,400 g for 30 min at 4C. The re-
sulting supernatant was removed and used as the membrane fraction. Both
fractions were subjected to SDS-PAGE and immunoblot analysis. The per-
centage of protein in the membrane fraction (membrane/cytosol + membrane)
was determined in at least three independent experiments by quantitative
immunoblot analysis using an Odyssey Infrared Imaging System (LI-COR
Corporate).
F11:Myosin-9A Interactions
Hek293T cells were transfected with CMV expression vectors encoding GFP-
tagged Myosin-9A or DPBM for 24 hr prior to infection with WR. Three hours
postinfection, cells were lysed in 25 mM Tris-HCl (pH 7.5), 1 mM EDTA, 10%
glycerol, 500 mM NaCl, 1% Triton-X, 1 mM Na3VO4, and protease inhibitors
(lysis buffer). The infected cell lysate was incubated with GFP-trap beads
(Chromotek) for 1 hr at 4C. The beads were subsequently washed three times
with lysis buffer containing first 500 and then 50 mM NaCl. Total input and
immunoprecipitated samples were subjected to SDS-PAGE and immunoblot
analysis.
Human A549 cells infected with recombinant virus expressing FLAG-F11 for
3 hr were lysed in PBS containing 0.5% Triton-X and protease inhibitors. The
cell lysate was incubated with anti-FLAG M2 Affinity resin (Sigma-Aldrich) for
1 hr at 4C, and the beads were subsequently washed three times with
PBS-lysis buffer. Total input and immunoprecipitated samples were subjected
to SDS-PAGE and immunoblot analysis.
To investigate the F11:Myosin-9A:RhoA complex, human A549 cells in-
fected with recombinant virus expressing FLAG-F11 for 3 hr were lysed in
Mg2+ lysis/wash buffer (Millipore) containing protease inhibitors. The cell lysate
was incubated with anti-FLAGM2 Affinity resin (Sigma-Aldrich) for 1 hr at 4C,
and the beads were subsequently washed three times with Mg2+ lysis/wash
buffer. Total input and immunoprecipitated samples were subjected to SDS-
PAGE and immunoblot analysis.
RNAi Transfections
The following RNAi were used: All-Star control (QIAGEN), siGENOME Human
Myosin9A siRNA (MYO9A-1, 50-GAAAGAAGCUUAGCCCUUA-30; and
MYO9A-3, 50-GAACAUACAUUACGGAUAU-30) (Dharmacon), siRNA against
the 30UTR of human Myosin-9A (50-CCUCUAUUUUAAGAUUUCU-30). HeLa
cells were transfected with 20 nM of each oligo using the HiPerfect fast-for-
ward protocol (QIAGEN). After 48 hr, the cells were infected with WR or
DF11 viruses. In addition, HeLa cells treated with Myosin-9A 30UTR or control
RNAi for 48 hr were also transfected with GFP-tagged Myosin-9A, R2098M,
and DPBM pEL expression vectors 1 hr postinfection. In both cases, infected
cells were fixed 8 hr postinfection and processed for immunofluorescence to
assess actin tail number as described previously (Arakawa et al., 2007a).
Statistical Analysis
Data are presented as mean ± standard error of the mean and were analyzed
by ANOVA or Student’s t test using Prism 6.0 (GraphPad Software, CA). A p
value of <0.05 was considered statistically significant.CSUPPLEMENTAL INFORMATION
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